Human immunoglobulin for diabetic amyotrophy - a promising prospect?

Diabetic neuropathies are universally recognised and cause significant morbidity. At present improving glycaemic control is the only recognised treatment. A man with type 2 diabetes presented with disabling asymmetric lower Limb proximal neuropathy. Rapid clinical, functional, and electrical improvement followed treatment with intravenous Immunoglobulin. The aetiology of diabetic amyotrophy remains controversial but there is evidence for an immune mediated process and this case suggests a role for immunoglobulin in the management of this debilitating condition.